001360.KS
SAMSUNG PHARM. Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 1,330.00
−0.08%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 42.7B | 46.1B | 44.3B | 52.0B | 51.8B |
| Cost of Revenue | 26.3B | 31.4B | 24.5B | 29.0B | 27.2B |
| Gross Profit | 16.5B | 14.6B | 19.8B | 23.0B | 24.6B |
| Operating Expenses | |||||
| R&D Expense | 3.4B | 3.5B | 1.3B | 2.3B | 327.0M |
| SG&A Expense | 28.4B | 24.8B | 25.3B | 33.3B | 32.7B |
| General & Admin Expense | 15.3B | 1.1B | 965.9M | 1.0B | 1.2B |
| Selling & Marketing Expense | 6.3B | 23.7B | 24.4B | 32.3B | 31.5B |
| Other Expenses | 2.9B | 5.9B | 8.0B | 5.4B | 5.6B |
| Total Operating Expenses | 33.3B | 34.1B | 34.6B | 41.0B | 38.6B |
| Cost and Expenses | 59.5B | 65.5B | 59.1B | 70.0B | 65.8B |
| Operating Income (EBIT) | (16.8B) | (19.5B) | (14.8B) | (18.0B) | (14.0B) |
| Non-Operating | |||||
| Interest Income | 920.9M | 1.1B | 810.3M | 806.7M | 726.5M |
| Interest Expense | 2.5B | 1.2B | 231.0M | 73.4M | 111.1M |
| Net Interest Income | (1.6B) | (116.3M) | 579.3M | 733.3M | 615.4M |
| Other Non-Op Income/Expense | (120.3B) | 31.0B | 736.9M | (5.6B) | (11.1B) |
| Non-Operating Income (excl Interest) | 53.0B | — | (968.0M) | 5.6B | 11.0B |
| EBT (Pre-Tax Income) | (137.2B) | 11.5B | (14.1B) | (23.7B) | (25.1B) |
| Income Tax Expense | — | — | — | 1.1B | — |
| Bottom Line | |||||
| Net Income | (137.2B) | 11.5B | (14.1B) | (24.8B) | (25.1B) |
| Earnings from Cont. Ops | (137.2B) | 11.5B | (14.1B) | (24.8B) | (25.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (136.6B) | 11.5B | (14.1B) | (24.8B) | (25.1B) |
| Per Share | |||||
| Basic EPS | (₩1,451) | ₩123 | (₩156) | (₩334) | (₩337) |
| Diluted EPS | (₩1,460) | ₩123 | (₩156) | (₩334) | (₩337) |
| Revenue Per Share | ₩454 | ₩489 | ₩491 | ₩699 | ₩697 |
| Shares | |||||
| Basic Shares Outstanding | 94.1M | 94.2M | 90.2M | 74.3M | 74.4M |
| Diluted Shares Outstanding | 94.1M | 94.2M | 90.2M | 74.3M | 74.4M |
| Profitability Metrics | |||||
| EBITDA | (16.0B) | (18.1B) | (11.7B) | (21.7B) | (22.0B) |
| D&A | 822.3M | 1.4B | 2.1B | 1.9B | 3.0B |
| EBIT | (16.8B) | (19.5B) | (13.9B) | (23.6B) | (25.0B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026